MedTrace Logo

Neo-adjuvant Trial With AZD9291 in EGFRm+ Stage IIIA/B NSCLC

NCT02824952 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-11-18

No results posted yet for this study

Summary

Patients will receive AZD9291 at a dose of 80 mg once daily. Systemic evaluation will be done by PET-CT scan after 6 weeks.

In responding patients AZD9291 will be given orally 80 mg daily for 12 weeks. Non-responding patients will receive AZD9291 for the period of 6 or 12 weeks (according to the results of response assessment at each time-point).

Conditions

  • Lung Cancer, Non-small Cell

Interventions

DRUG

Tagrisso

taking orally everyday for 6 or 12 weeks.

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Shaare Zedek Medical Center

    lead OTHER

Principal Investigators

  • Nir Peled, MD PhD FCCP · Shaare Zedek Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-01
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02824952 on ClinicalTrials.gov